Nova2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-85393
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
1 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the N-terminal region of human Nova2. Peptide sequence: MEPEAPDSRKRPLETPPEVVCTKRSNTGEEGEYFLKVLIPSYAAGSIIGK The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Scientific Data Images for Nova2 Antibody
Western Blot: Nova2 Antibody [NBP2-85393]
Western Blot: Nova2 Antibody [NBP2-85393] - Lanes: 1. 10 ug human neural cell lysate. 2. 10 ug human non-neural cell lysate. Primary Antibody Dilution: 1:1000. Secondary Antibody: Goat anti-rabbit IRDye 800 (1hr room temperature). Secondary Antibody Dilution: 1:15,000. Gene Name: NOVA2. Submitted by: Dr. Monica Faronato, University of Liverpool.Western Blot: Nova2 Antibody [NBP2-85393]
Western Blot: Nova2 Antibody [NBP2-85393] - WB Suggested Anti-NOVA2 Antibody Titration: 1.25ug/ml. Positive Control: HepG2 cell lysateApplications for Nova2 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Nova2
Alternate Names
neuro-oncological ventral antigen 2ANOVANOVA3Astrocytic NOVA1-like RNA-binding protein, neuro-oncological ventral antigen 3, RNA-binding protein Nova-2
Gene Symbol
NOVA2
Additional Nova2 Products
Product Specific Notices for Nova2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...